MAZE
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Maze Therapeutics, Inc.
- Nom
- Maze Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.8B
- Employés
- 141
- PDG
- Jason Coloma
- Site web
- https://www.mazetx.com
- Marché
- ARDXBIOADMACIVAPTCTSEPN
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 22 638 titres (~592 961,12 $ US)
- Insiders
- Coloma Jason V
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,201,518
Avg sell (VWAP, 90d window) $26.93 vs last close $26.25 (-2.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,123,739 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-03
- Liquidity
- Liquid $24,583,784/day · 20d vol
- Last synced
-
2026-10-07 21:10:37
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Bernstein Harold | Sell · S · 10b5-1 | 16,141 | $26.93 | $434,743 | Form 4 |
| 2026-10-01 | Coloma Jason V | Sell · S · 10b5-1 | 2,593 | $27.02 | $70,073 | Form 4 |
| 2026-09-29 | Dandekar Atul | Sell · S · 10b5-1 | 7,500 | $27.06 | $202,921 | Form 4 |
| 2026-09-04 | Bernstein Harold | Sell · S · 10b5-1 | 9,705 | $26.22 | $254,502 | Form 4 |
| 2026-09-03 | Bernstein Harold | Sell · S | 59 | $25.78 | $1,521 | Form 4 |
| 2026-09-03 | Coloma Jason V | Sell · S | 129 | $25.77 | $3,325 | Form 4 |
| 2026-09-03 | Courtney Phillips | Sell · S | 22 | $25.78 | $567 | Form 4 |
| 2026-09-03 | Dandekar Atul | Sell · S | 36 | $25.81 | $929 | Form 4 |
| 2026-09-02 | Bernstein Harold | Sell · S | 625 | $27.12 | $16,951 | Form 4 |
| 2026-09-02 | Coloma Jason V | Sell · S | 1,375 | $27.12 | $37,292 | Form 4 |
| 2026-09-02 | Courtney Phillips | Sell · S | 243 | $27.12 | $6,590 | Form 4 |
| 2026-09-02 | Dandekar Atul | Sell · S | 391 | $27.12 | $10,604 | Form 4 |
| 2026-09-01 | Bernstein Harold | Sell · S · 10b5-1 | 16,141 | $26.36 | $425,512 | Form 4 |
| 2026-09-01 | Coloma Jason V | Sell · S · 10b5-1 | 2,593 | $26.31 | $68,214 | Form 4 |
| 2026-08-28 | Dandekar Atul | Sell · S · 10b5-1 | 7,500 | $27.58 | $206,824 | Form 4 |
| 2026-08-13 | Bernstein Harold | Sell · S · 10b5-1 | 16,142 | $27.61 | $445,621 | Form 4 |
| 2026-08-03 | Coloma Jason V | Sell · S · 10b5-1 | 154 | $27.09 | $4,172 | Form 4 |
| 2026-07-29 | Dandekar Atul | Sell · S · 10b5-1 | 400 | $27.89 | $11,156 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
MAZE presents a deeply concerning profile: despite strong short-term liquidity (score 85), the complete collapse in revenue and profitability in 2025 renders the business model highly precarious.
The first sentence of the analysis written for MAZE on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 15.50 · operating margin 0.0%
Suggested stop 24.48, nearest stored support minus 0.5 ATR(6.7% under the last close). Reward/risk to the next stored resistance is 1.09. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 31.9% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 33.9% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 34.4% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 31.9% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 31.2% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 31.2% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 2.0% | 0.0% | 0.0% | |
| Current Ratio | 15.504 | 9.755 | 2.091 | 5.107 | |
| Quick Ratio | 15.504 | 9.755 | 2.091 | 5.107 | |
| Solvency Ratio | -3.053 | 1.272 | -1.568 | -2.290 | |
| Cash Ratio | 8.390 | 9.520 | 1.787 | 4.808 | |
| Price To Earnings Ratio | -13.584 | 205.013 | -6.954 | -6.075 | |
| Price To Earnings Growth Ratio | 0.003 | -1.983 | 0.550 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.003 | -1.983 | 0.550 | 0.000 | |
| Price To Earnings Diluted Ratio | -13.584 | 205.013 | -6.954 | -6.075 | |
| Price To Earnings Diluted Growth Ratio | 0.003 | -1.983 | 0.550 | 0.000 | |
| Price To Book Ratio | 5.016 | 3.548 | 69.449 | 6.883 | |
| Price To Sales Ratio | 0.000 | 4.170 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -15.794 | 9.338 | -8.001 | -6.902 | |
| Price To Operating Cash Flow Ratio | -15.906 | 9.197 | -8.042 | -7.039 | |
| Debt To Assets Ratio | 0.059 | 0.111 | 0.694 | 0.214 | |
| Debt To Equity Ratio | 0.066 | 0.135 | 4.936 | 0.316 | |
| Debt To Capital Ratio | 0.062 | 0.119 | 0.832 | 0.240 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.666 | 0.000 | |
| Financial Leverage Ratio | 1.119 | 1.222 | 7.112 | 1.478 | |
| Working Capital Turnover Ratio | 0.000 | 1.685 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.963 | 3.674 | -5.322 | -4.773 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.453 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 0.985 | 1.005 | 1.020 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -4.803 | 2.852 | -1.750 | -3.095 | |
| Capital Expenditure Coverage Ratio | -140.982 | 66.220 | -196.887 | -50.459 | |
| Dividend Paid And Capex Coverage Ratio | -140.982 | 66.220 | -196.887 | -50.459 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.543 | 9.319 | -7.461 | -5.673 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▼-100.0% | ▼-25.0% |
| Ebit Margin | 0.0% | ▼-31.9% | ▼-8.0% |
| Ebitda Margin | 0.0% | ▼-33.9% | ▼-8.5% |
| Operating Profit Margin | 0.0% | ▼-34.4% | ▼-8.6% |
| Pretax Profit Margin | 0.0% | ▼-31.9% | ▼-8.0% |
| Continuous Operations Profit Margin | 0.0% | ▼-31.2% | ▼-7.8% |
| Net Profit Margin | 0.0% | ▼-31.2% | ▼-7.8% |
| Bottom Line Profit Margin | 0.0% | ▼-2.0% | ▼-0.5% |
| Current Ratio | 15.504 | ▲5.749 | ▲7.390 |
| Quick Ratio | 15.504 | ▲5.749 | ▲7.390 |
| Solvency Ratio | -3.053 | ▼-4.325 | ▼-1.643 |
| Cash Ratio | 8.390 | ▼-1.130 | ▲2.264 |
| Price To Earnings Ratio | -13.584 | ▼-218.596 | ▼-58.184 |
| Price To Earnings Growth Ratio | 0.003 | ▲1.986 | ▲0.361 |
| Forward Price To Earnings Growth Ratio | 0.003 | ▲1.986 | ▲0.361 |
| Price To Earnings Diluted Ratio | -13.584 | ▼-218.596 | ▼-58.184 |
| Price To Earnings Diluted Growth Ratio | 0.003 | ▲1.986 | ▲0.361 |
| Price To Book Ratio | 5.016 | ▲1.468 | ▼-16.208 |
| Price To Sales Ratio | 0.000 | ▼-4.170 | ▼-1.043 |
| Price To Free Cash Flow Ratio | -15.794 | ▼-25.132 | ▼-10.454 |
| Price To Operating Cash Flow Ratio | -15.906 | ▼-25.103 | ▼-10.459 |
| Debt To Assets Ratio | 0.059 | ▼-0.052 | ▼-0.211 |
| Debt To Equity Ratio | 0.066 | ▼-0.070 | ▼-1.298 |
| Debt To Capital Ratio | 0.062 | ▼-0.058 | ▼-0.252 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.167 |
| Financial Leverage Ratio | 1.119 | ▼-0.103 | ▼-1.614 |
| Working Capital Turnover Ratio | 0.000 | ▼-1.685 | ▼-0.421 |
| Operating Cash Flow Ratio | -4.963 | ▼-8.637 | ▼-2.117 |
| Operating Cash Flow Sales Ratio | 0.000 | ▼-0.454 | ▼-0.113 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▲0.022 | ▲0.003 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -4.803 | ▼-7.655 | ▼-3.104 |
| Capital Expenditure Coverage Ratio | -140.982 | ▼-207.202 | ▼-60.455 |
| Dividend Paid And Capex Coverage Ratio | -140.982 | ▼-207.202 | ▼-60.455 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.543 | ▼-21.862 | ▼-8.454 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $1.78B | $698.5M | $698.2M | $698.2M | |
| Enterprise value | $1.61B | $528.4M | $718.7M | $630.4M | |
| EV / Sales | 0.00x | 3.15x | 0.00x | 0.00x | |
| EV / Op. cash flow | -14.42x | 6.96x | -8.28x | -6.35x | |
| EV / Free cash flow | -14.32x | 7.06x | -8.24x | -6.23x | |
| EV / EBITDA | -12.54x | 9.32x | -7.46x | -5.67x | |
| Net debt / EBITDA | 1.29x | -3.00x | -0.21x | 0.61x | |
| Current ratio | 15.50x | 9.76x | 2.09x | 5.11x | |
| Income quality | 0.85x | 1.45x | 0.86x | 0.86x | |
| Graham number | — | $11 | — | — | |
| Graham net-net | $7 | $3 | -$1 | $1 | |
| Tax burden | 100.0% | 97.8% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $327.2M | $181.0M | $17.8M | $85.4M | |
| Invested capital | $352.3M | $210.9M | $52.8M | $126.6M | |
| Return on assets | -33.0% | 21.7% | -140.4% | -76.6% | |
| Operating ROA | -44.8% | 36.9% | -89.0% | 0.0% | |
| Return on tangible assets | -33.0% | 21.7% | -140.4% | -76.6% | |
| Return on equity | -36.9% | 26.5% | -998.8% | -113.3% | |
| Return on invested capital | -37.7% | 25.1% | -165.1% | -83.2% | |
| Return on capital employed | -38.2% | 26.2% | -178.6% | -86.0% | |
| Earnings yield | -7.4% | 7.5% | -14.4% | -16.5% | |
| Free cash flow yield | -6.3% | 10.7% | -12.5% | -14.5% | |
| Capex / Op. cash flow | -0.7% | 1.5% | -0.5% | -2.0% | |
| Capex / Depreciation | 33.0% | 34.8% | 10.8% | 51.5% | |
| Capex / Sales | 0.0% | 0.7% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 15.8% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 49.8% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 5.8% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 272d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -272d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-07 Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Position Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 10.2% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,032,915 shares of the company''s stock after acquiring an additional 465,641 shares during the period. Maze Therapeutics accounts
- 2026-09-02 Maze Therapeutics to Participate in Three Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in three upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference; fireside chat on Wednesday, September 9, 2026, at 9:30 a.m.
- 2026-08-30 BlackRock Inc. Purchases Shares of 3,502,841 Maze Therapeutics, Inc. $MAZE BlackRock Inc. purchased a new position in Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,502,841 shares of the company''s stock, valued at approximately $104,525,000. BlackRock Inc. owned approximately 6.33% of Maze Therapeutics as
- 2026-08-27 Bank of America Corp DE Purchases 176,703 Shares of Maze Therapeutics, Inc. $MAZE Bank of America Corp DE increased its holdings in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 961.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 195,084 shares of the company''s stock after buying an additional 176,703 shares during the period. Bank of America Corp DE
- 2026-08-26 Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist Maze Therapeutics, Inc. has advanced two lead precision medicine programs, MZE782 for PKU and MZE829 for APOL1-mediated kidney disease, with significant clinical progress. MZE782 demonstrated a best-in-class pharmacodynamic profile in Phase 1, supporting a transformative potential for PKU management; Phase 2 is set for mid-2026. MZE829 achieved strong uACR reductions in early Phase 2 data for AMKD, but faces competition from Vertex''s inaxaplin; pivotal trials are planned for 1H 2027.
- 2026-08-26 ARCH Venture Management LLC Makes New $122.98 Billion Investment in Maze Therapeutics, Inc. $MAZE ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics, Inc. (NASDAQ: MAZE) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,120,053 shares of the company''s stock, valued at approximately $122,983,582,000. Maze Therapeutics accounts for about 11.2% of ARCH Venture Management
- 2026-08-13 Maze Therapeutics Announces Appointments to Its Board of Directors Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze''s Board of Directors, adding to the Company''s deep bench of clinical and industry experience
- 2026-08-11 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and marketable securities supports expected runway into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the second quarter ended June 30, 2026, highlighting recent progress and business updates.
- 2026-07-21 Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-06-29 What Does the Maze Therapeutics CEO''s Sale of Nearly 30,000 Shares Mean for Investors? This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.